Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 3, 2018updated 12 Aug 2019 10:38am

Deals this week: Savara, Tiziana Life Sciences, Verastem

Savara plans to raise $48.9m through an underwritten public offering of more than four million shares of its common stock priced at $11.5 a share.

Savara plans to raise $48.9m through an underwritten public offering of more than four million shares of its common stock priced at $11.5 a share.

The underwriters will have a 30-day option to buy an additional 0.63 million shares of the company’s common stock.

Based in the US, Savara is a clinical-stage pharmaceutical company focused on the development of novel drugs for the treatment of rare and life-threatening respiratory diseases.

The company plans to use the funds towards clinical development, working capital, and other general corporate purposes.

Wilson Sonsini Goodrich & Rosati has been appointed as the legal adviser to the company for the offering.

UK-based biotechnology company Tiziana Life Sciences has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $11.79m through an initial public offering of American Depositary Shares (ADS).

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The underwriters will be granted a 30-day option to buy additional shares as part of the offering.

Laidlaw & Company (UK) has been appointed as the underwriter to the company for the offering.

The company plans to use the funds for clinical development activities, working capital, and general corporate purposes.

Verastem plans to issue securities through a public offering to raise $200m.

The company intends to issue the securities periodically in any combination of common stock, preferred stock, and warrants.

Based in the US, Verastem is a biopharmaceutical company engaged in the development and commercialisation of drugs for cancer treatment.

“Verastem plans to issue securities through a public offering to raise $200m.”

The funds raised through the offering are intended to be used towards research and development (R&D), clinical trial expenditures, and working capital.

Ropes & Gray has been appointed as the legal adviser to the company for the offering.

Caladrius Biosciences plans to issue securities in a public offering to raise $150m.

The company intends to issue the securities periodically in any combination of common stock, preferred stock, and warrants.

Based in the US, Caladrius Biosciences is a clinical-stage biopharmaceutical company that develops therapies and regenerative medicines for cardiovascular diseases.

The funds raised through the offering are intended to be used towards research and development (R&D), business expansion, and other general corporate purposes.

Mintz Levin Cohn Ferris Glovsky and Popeo has been appointed as the legal adviser to the company for the offering.

Omniome has raised $60m through a series B funding round led by Decheng Capital and Hillhouse Capital Group.

The funding round also included participation from Lam Research Capital and Nan Fung Life Sciences and existing investors ARCH Venture Partners, Domain Associates and Altitude Life Science Ventures.

Based in the US, Omniome is a biotechnology company focused on the development of DNA sequencing platform.

The company plans to use the funds towards hiring new employees and accelerating the development of its sequencing by binding (SBB) platform.

ContraFect has raised $10m through an underwritten public offering of five million shares of its common stock priced at $2 a share.

The underwriters will have a 30-day option to buy an additional 0.75 million shares of the company’s common stock.

Based in the US, ContraFect is a biotechnology company that develops therapies for life-threatening diseases.

The company plans to use the funds towards clinical development, working capital, and other general corporate purposes.

Latham & Watkins has been appointed as the legal adviser to the company for the offering.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU